RT Journal Article SR Electronic T1 The Adjunctive Effect of Nebulized Furosemide in COPD Exacerbation: A Randomized Controlled Clinical Trial JF Respiratory Care FD American Association for Respiratory Care SP 1873 OP 1877 DO 10.4187/respcare.02160 VO 58 IS 11 A1 Hojat Sheikh Motahar Vahedi A1 Babak Mahshidfar A1 Helaleh Rabiee A1 Soheil Saadat A1 Hamid Shokoohi A1 Mojtaba Chardoli A1 Vafa Rahimi-Movaghar YR 2013 UL http://rc.rcjournal.com/content/58/11/1873.abstract AB OBJECTIVE: To examine the effect of nebulized furosemide as an adjunct to the conventional treatment of patients with COPD exacerbation in an emergency department. METHODS: In this randomized double-blinded clinical trial, patients with COPD exacerbation were randomized to receive 40 mg nebulized furosemide or placebo as an adjunct to the conventional treatments. We recorded changes in dyspnea severity (measured with a visual analog scale), FEV1, arterial blood gas measurements, blood pressure, heart rate, and breathing frequency at baseline and 1 hour after treatment. RESULTS: We randomized 100 patients, whose mean age was 73.1 ± 8.7 y. The measured variables all improved significantly in both groups. FEV1, dyspnea, pH, mean blood pressure, and heart rate improved significantly more in the furosemide group. CONCLUSIONS: Nebulized furosemide benefits patients with COPD exacerbation.